Eli Lilly and Company (LLY)
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care
LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to the space.
Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Is It Too Late To Buy The Rally In Eli Lilly Stock?
This article was written and reviewed by Doug Nathman and his team at Trefis. For questions, email [email protected].
Prediction: Eli Lilly Will Trade at This Price in a Year
Eli Lilly (NYSE:LLY | LLY Price Prediction) is finally acting like a trillion-dollar drugmaker again.
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
Eli Lilly stock rises as Retatrutide data boosts obesity drug lead
Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide. This has reinforced investor confidence in the company's long-term position in the rapidly expanding weight-loss market.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.
